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In order to clarify whether nocturnal hypoxaemia (arterial oxygen saturation, SaO, ~90%) may exist in the 
long-term before daytime hypoxaemia (PaO, ~8.0 kPa) occurs in chronic obstructive pulmonary disease (COPD), 
21 patients with stable severe COPD without daytime hypoxaemia (PaO, 28.0 kPa) were studied prospectively. 
Subjects were monitored twice by polysomnography (PSG) 12 months apart. Spirometry was performed, and 
diffusion capacity (DLCO) and hypercapnic respiratory drive response API,., dPC0, - ‘) were measured during the 
daytime in conjunction with polysomnography. 
At the start of the study our subjects had FEV,%P (FEV, as a percentage of predicted value) of 26.1 & 7.2%, a 
mean nocturnal nadir SaO, of 83 * 5%, and a mean SaO, during nocturnal hypoxaemic episodes of 88.0 f 0.7%. 
The patients’ ~PI,., dPCO,- ’ was 1.8 f 1.4 cm H,O kPa- ’ (within the normal range). For the entire study group, 
no significant change in any lung function or blood gas parameter was noted during the year of observation, and 
nocturnal SaO, remained unaltered. Stage I sleep decreased (BO.05) after 12 months. Prolonged stage I sleep was 
associated with nocturnal hypoxaemia at the second PSG. Five subjects developed daytime hypoxaemia and they 
showed poorer lung function but similar nocturnal hypoxaemia and ~PI,., BPCO, - ’ level compared to the rest of 
the patients. Patients with sudden SaO, dips had more pronounced nocturnal hypoxaemia and prolonged 
wakefulness than ‘non-dippers’. 
In conclusion, the mean level of nocturnal hypoxaemia may persist unaltered for at least 1 yr. COPD patients with 
exclusively nocturnal hypoxaemia have a hypercapnic drive response within the normal range. Prolonged nocturnal 
hypoxaemia and reduced whole night oxygenation are associated with increased superficial sleep. Sleep fragmenta- 
tion and high carbon dioxide sensitivity may be important defence mechanisms against sleep-related hypoxaemia. 
The appearance of daytime hypoxaemia is preceded by a substantial deterioration in lung function, but by only 
a minor deterioration of nocturnal hypoxaemia. 
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Introduction 
Nocturnal hypoxaemia (nocturnal arterial oxygen satura- 
tion, SaO, <90%), is found in about 25% of patients with 
severe COPD and daytime arterial oxygen tension (PaO,) 
of at least 8.0 kPa (1). To our knowledge, however: no 
prospective study has been performed to examine whether 
sleep-related hypoxaemia is just a transient state prior to 
the development of daytime hypoxaemia, or whether 
nocturnal hypoxaemia may exist for long periods in COPD 
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patients before the appearance of daytime respiratory 
insufficiency. 
Fletcher et al. (2) found that a majority of patients with 
sudden profound desaturations (‘dippers’) had poorer lung 
function and were eventually more prone to reductions in 
nocturnal or daytime SaO, than subjects with plateau- 
shaped hypoxaemic episodes (‘non-dippers’). It is not 
known whether such hypoxaemic patterns change over time 
in the individual patient. 
Severe nocturnal hypoxaemic episodes have been found 
particularly in COPD patients with pronounced daytime 
hypoxaemia, since their SaO, levels are situated on the 
steep portion of the haemoglobin dissociation curve (3-6). 
The deepest and most frequent desaturations occur during 
REM sleep. The main mechanism causing nocturnal 
desaturations - especially during REM sleep - is periodic 
hypoventilation, which in turn is believed to be due to 
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decreased activity of the intercostal muscles and reduced 
chemical respiratory drive (7-10). Chemical respiratory 
drive and sleep fragmentation have been found to be the 
most important defence mechanisms against sleep- 
related blood gas derangements in other diseases, such as 
neuromuscular and chest-wall disorders (11). In COPD, 
however, the role of these defence mechanisms is less clear. 
Ventilatory response to hypercarbia (HCVR) during 
daytime is a possible predictor of nocturnal hypoxaemia in 
COPD patients with daytime normoxaemia (12). However, 
ventilatory response is influenced not only by the central 
respiratory drive, but also by the respiratory system’s 
resistance and compliance, and further by vagal volume- 
related reflexes (13,14). Such confounding factors may be 
avoided by measuring inspiratory occlusion pressure during 
the first 0.1 s of inspiration (PI,.,), i.e. before the subject is 
conscious of the inspiratory manoeuvre (13,14). A possible 
relationship between daytime PI,., and nocturnal 
hypoxaemia in COPD patients has not previously been 
examined. 
It has been found that COPD patients with daytime 
respiratory insufficiency have more intervening wakeful- 
ness, more frequent sleep stage changes and a lower total 
amount of sleep than age-matched healthy controls (6,16). 
Other studies have failed to demonstrate any differences in 
sleep quality between hypoxaemic COPD patients and 
healthy controls (3,1.5). 
Brief arousals in COPD patients are more common in 
COPD than in healthy persons (15,16) but no temporal 
relationship has been noted between nocturnal hypoxaemic 
episodes and brief arousals in COPD. A possible relation- 
ship between change over time in quality of sleep and 
change in the severity of nocturnal hypoxaemia has not 
been the subject of previous prospective investigation. 
In order to follow the long-term development of noctur- 
nal hypoxaemia and patterns in hypoxaemia, and also to 
examine these variables’ relationships to sleep quality and 
chemical respiratory drive (as assessed by daytime carbon 
dioxide responsiveness), all of these parameters were 
measured in 21 COPD patients on two occasions 12 months 
apart. Clinical outcomes were monitored for a further 2 yr. 
Subjects 
Twenty-one patients (three smokers and 18 ex-smokers) 
made up the study group. Their mean age at the start of the 
study was 62 (range 45-70) years. All patients had severe 
COPD, with a mean duration of 13 (range 540) years, a 
forced expiratory volume in 1 s (FEV, %P) of <40%, and a 
FEV,/vital capacity (VC) of ~70%. Two subjects had 
homozygotic a-1-antitrypsin deficiency. 
Our patients had a resting daytime PaO, value of at least 
8.0 kPa and no hypercarbia (Table 1). They were free from 
cardio-pulmonary exacerbations for at least 3 weeks prior 
to the nocturnal measurements. Care was taken to avoid 
inclusion of heavy snorers or spouse-witnessed sleep 
apnoeas. Patients abusing alcohol were not included in the 
study. All patients were followed for a total of 36 months 
from their inclusion in the study, or until their death. One 
TABLE 1. Anthropometric lung function and CO, response 
PSG 1 PSG 2 
(Mean f SD) (Mean f SD) 
Age (years) 62 rt 6 
BMI (kg m - 2) 20.5 zt 2.8 20.6 f 3.0 
FVC (%P) 62.3 zt 15.4 63.7 f 17.3 
FEV, (%P) 26.1 zt 7.2 21.4 f 9.0 
RV (%P) 174.0 + 39.8 174.7 It 53.1 
vc (%P) 73.0 it 13.6 73.6 it 14.8 
TLC (%P) 109.1 * 13.9 108.8 * 15.7 
Diff. cap.* (%P) 30.3 * 9.7 
PaO, (kPa) 9.8 It 1.4 9.7 * 1.4 
PaCO, (kPa) 5.4 + 0.6 5.4 * 0.5 
&‘I,., dPCO,-‘(cmH,OkPa- ‘) 1.8 & 1.4 1.3 * 1.1 
HCVR (1 min - ’ kPa) 3.7 zk 3.8 6.4 zk 4.7 
Min. vent. (1 min - I) 11.1 & 1.4 10.3 i 1.4 
No significant changes between PSGl and PSG 2 were 
noted. 
*Only recorded at the second polysomnography. 
patient who developed a daytime PaO, value of less than 
7.5 kPa during the study and was given LTOT and another 
patient who declined to participate in a second registration 
were excluded from nocturnal and daytime physiological 
measurements. From that moment these two patients’ 
clinical outcome was monitored further for 3 consecutive 
yrs after their inclusion in the study. 
Patients’ lung function and arterial blood gases were 
checked at our outpatient clinic every third month. They 
continued to receive their ordinary medication throughout 
the study period. All subjects used P,-agonists, 18 took oral 
slow-release theophylline preparations, and 16 inhaled 
corticosteriods. Ten patients used diuretics at the start of 
the study. One yr later, 14 received diuretics regularly in 
order to counteract an increased tendency to peripheral 
oedema. Otherwise, medication remained unaltered. 
Neither hypnotics nor anxiolytics were prescribed to the 
patients. One patient was excluded from the study because 
of difficulties in sleeping with the equipment. 
Ten healthy males without a history of lung disease and 
with a mean age of 40.8 + 8.7 years were used as controls 
for the carbon dioxide responsiveness measurements. There 
was no control group regarding sleep registrations. 
The study was approved by the Ethical Committee of 
Huddinge University Hospital, and all subjects gave their 
informed consent. 
Methods 
Polysomnography (PSG) was performed at the start of the 
study and repeated after 12 months. The patients slept 
alone in a quiet room for two nights. During the first night, 
they got accustomed to the monitoring equipment, and no 
data were collected until the second night. 
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Standard sleep variables, including electroencephalo- 
gram, electro-oculogram and submental electromyogram, 
were measured using surface electrodes (17). Respiratory 
movements of the thorax were monitored by pneumobelts 
connected to pressure transducers (Respitrace Corporation, 
U.S.A.). Nasal and oral airflows were recorded by 
thermistors. Nocturnal SaO, was recorded continuously 
with a finger-pulse oxymeter (Radiometer AS, Copen- 
hagen). All variables were simultaneously monitored by 
polygraph. 
Total sleep period (TSP) was defined as time from first 
occurrence of sleep stage 11 to final awakening (18). Periods 
of wakefulness occurring after the first appearance of sleep 
stage II and before final awakening were included in TSP. 
Sleep onset (SO) latency was calculated as time between 
‘lights out’ and first period of sleep stage II. The sum of 
sleep stages II-IV and REM sleep was designated as proper 
sleep time (15). The minimum sleep period accepted for 
analysis of sleep recordings was 3 h. 
Dips were defined using the following modification of 
Fletcher’s definition (1,2) as sudden desaturations (from the 
supine baseline SaO, before falling asleep) lasting for at 
least 1 min and with a nadir SaO, level lower than 85%. 
The average SaO, during the whole night was designated 
mean SaO,. A SaO, value below 90% was defined as 
hypoxaemia. Mean SaO, during a whole night’s hypoxae- 
mic episodes was denominated as mean hypoxaemic SaO,. 
Arterial radial blood gas analyses (ABL 520, Radiometer 
AS, Copenhagen, Denmark) were performed in the 
evening, 1 h before the start of the polysomnographic 
recording (at about 1000h) and 2 h after its completion in 
the morning (at about 0900h). Blood gas samples were 
taken when the patients were awake, resting in a supine 
position. 
Carbon dioxide responsiveness was measured by a modi- 
fied Read’s test (19). The patients were sitting and relaxing 
(listening to music), wearing a nose clip. When the patients 
became accustomed to the measuring equipment and 
attained quiet tidal volume breathing, they started to 
rebreathe from an 8-l plastic cylinder filled with a gas 
mixture of 6.5% CO, in 93.5% 0,. Changes in gas volume 
were assessed by use of a compliant rubber bag connected 
to a pneumotachygraph within a Servo ventilator (SV9OOC, 
Siemens Elema Ltd, Stockholm). This system was used to 
estimate changes in minute ventilation in response to 
increasing CO, levels. End-tidal CO, values were recorded 
continuously by means of an infrared analyser (Datex 
Oscar Oxy, Helsinki, Finland). The dead space of the 
equipment was less than 200 ml, and the resistance of the 
systemuptoaflowof1~51s~‘was0~5cmH,01s-’.The 
slope of the linear regression line describing change in 
minute ventilation in relation to change in end-tidal PCO, 
was defined as hypercapnic ventilatory response (HCVR). 
The subjects’ respiratory drive was estimated by means of 
inspiratory occlusion pressure (13,20). Brief occlusion of 
the inspiratory circuit at the onset of an inspiration was 
effected, and the inspiratory pressure drop per 0.1 s of 
occlusion (PI,,) was determined (20). Inspiratory pressure 
was measured by use of the pressure transducers within the 
Servo ventilator. The slope of the linear regression line 
describing change in PI,., in relation to change in end-tidal 
PCO, was defined as the hypercapnic respiratory drive 
response (API,., dPCO,-‘). 
Spirometry to measure hung function was performed with 
subjects in a sitting position. Measurements were taken of 
vital capacity (VC), forced vital capacity (FVC), forced 
expiratory volume during 1 s (FE?‘,), forced expiratory 
flow at 50% of FVC (MEF,,), forced expiratory flow at 
25% of FVC (MEF,,), and peak expiratory flow (PEF). 
Functional residual capacity (FRC), residual volume (RV), 
and total lung capacity (TLC) were determined by the 
helium dilution technique. All measurements were per- 
formed using a Pulmonary Function Laboratory 2400 
(Sensor Medics BV, Bilthoven, The Netherlands). The best 
FEV, value of three was accepted, and values of all other 
indices of forced airflow were read from that curve. 
The diffusion capacity for carbon monoxide (DLCO) was 
measured by means of the single-breath method (21). 
CO, sensitivity tests and lung function measurements 
were performed the day after the PSG. For technical 
reasons, CO, sensitivity was measured for 13 subjects at the 
first PSG, and 18 at the second. DLCO measurements were 
performed only in conjunction with the second PSG. 
STATISTICAL ANALYSES 
The significance of changes over time, and also changes 
between sleep stages, were assessed by the Wilcoxon signed- 
rank test. Differences between groups were assessed by the 
Mann-Whitney U-test. The Spearman rank correlation test 
was employed to determine correlations between variables. 
A P-value of below 0.05 was regarded as significant. Data 
are presented as mean * SD unless otherwise stated. 
Results 
LUNG FUNCTION 
At the beginning of the study, we found that all our patients 
suffered from severe irreversible airway obstruction clj2 
stimulation inducing less than a 10% increase in FEV,) and 
hyperinflation with an average (before p2 stimulation) 
FEV,%P of 26 & 7% and a RV%P of 174 Ifi- 40%. Daytime 
supine PaO, ranged between 8.0 and 11.5 kPa (Table 1). 
Minute ventilation measured during carbon dioxide 
rebreathing was significantly higher among patients at 
both first PSG (11.1 * l.Slmin~‘) and second PSG 
(10.3 f 1.4 1 min - i) than among healthy controls 
(8.6 * 0.9 1 min - ‘; P<O.OOl and WO.01, respectively). 
No spirometric or blood gas parameter changed signifi- 
cantly over the year of observation (with regard to the 
whole cohort) (Table 1). 
QUALITY OF SLEEP 
All but one patient (during one recording) attained REM 
sleep (range O-92 min; Table 2). Mean TSP at the first 
polysomnography (PSG) was 360 & 65 min. About 30% of 
TSP was spent in wakefulness and sleep stage I. Mean stage 
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TABLE 2. Sleep quality data 120, 
PSG 1 
(Mean & SD) 
PSG 2 




St 0 (% of TSP) 
St I (% of TSP) 
St II (% of TSP) 
St III+IV (% of TSP) 
REM (% of TSP) 
32 IIC 20 35 &26 
397 zt 57 402 zt 25 
360 rt 65 364 z!z 47 
16.9 zt 13.1 17.7 * 12.6 
12.6 & 5.6 *9.6 f. 5.8 
15.7 * 7.8 15.9 5 8.9 
41.1 zt 13.7 44.0 * 14.4 
13.8 * 5.6 17.7 f 12.6 
01 I I I I I 
SO, sleep onset latency; TIB, time in bed; TSP, total sleep 
period; St 0, wakefulness; St, sleep stages; REM, rapid eye 
movement sleep. 
*P<O.O5 between PSG 1 and PSG 2. 
84 86 88 90 92 94 96 
Mean SaO, (%) 
Except for sleep stage 1, no significant changes between 
PSG 1 and PSG 2 were noted. 
FIG. 1. Correlation between mean SaO, and total 
numbers of sleep stage changes at the second PSG 
(V’ - 0.54, PCO.05). 
HYPOXAEMIC PATTERNS 
II sleep lasted only 15.7 & 7.8% of TSP, while mean stage 
III-IV sleep comprised as much as 41.1 f 13.7% of TSP 
(Table 2). The number of sleep stage changes per TSP hour 
was in the upper range of normal (18). There were weak 
correlations between high daytime minute ventilation at the 
first PSG on the one hand and increased frequency of sleep 
stage changes and also with prolonged wakefulness as a 
percentage of TSP on the other hand (v=O,49 and v=O.47, 
respectively; PcO.05 for both). 
Between the first and second PSG there was a median 
decrease of 17% in sleep stage I as a percentage of TSP 
(PcO.05) (Table 2). Otherwise, no significant changes 
regarding sleep stages were noted (Table 2). 
CARBON DIOXIDE RESPONSIVENESS 
Mean supine baseline SaO, before TSP was 90.8 * 0.4% at 
the onset of the study. All patients with one exception had 
hypoxaemic episodes at both PSGs, and a further two at the 
first PSG. The mean nadir nocturnal SaO, value was 
82.6 * 5%, and mean hypoxaemic SaO, 88.0 & 0.7% at the 
start of the study. No significant changes in nadir or mean 
hypoxaemic SaO, were noted between the first and second 
PSGs (with regard to the entire group) (Table 3). However, 
the nadir SaO, value changed by more than 4 percentage 
points in seven subjects (increasing in four and decreasing 
in three), while no other patient changed their oxygen 
saturation by more than 2 percentage points. The mean 
hypoxaemic SaO, decreased by more than 2 units in only 
two subjects, while it remained virtually unaltered among 
all others. 
The average respiratory response to CO, rebreathing, as 
assessed by PI,.,, was 1.8 f 1.4 cm H,O kPa ~ i at the onset 
of the study which was not significantly different from 
the level of healthy controls (2.3 i. 1.7 cm H,O kPa- ‘). 
At second PSG, API,., APCO, - 1 was 1.26 zt 
1.1 cm H,O kPa- ’ not significantly different from the level 
at the start of the study, or from that of the healthy 
controls. A positive correlation between API,., APCO, ~ ' 
and RV%P was found at the start of the study (v=O.68, 
PiO.05). 
The HCVR value for the entire study group did not 
change significantly over the year. HCVR was 
3.7 * 3.8 1 min - ’ kPa - i of CO, at the beginning of the 
study. However, at the second PSG ventilatory response 
tended to increase with increasing levels of FEV, VC ’ 
(r=0.62, P=O.Ol). Our patients’ HCVR, measured in con- 
junction with both polysomnographies, was lower 
(P<O.OOl) than normal (23.6 & 10.8 1 min- ’ kPa- ‘). 
The median duration of nocturnal hypoxaemic episodes 
during the whole night was 92.5 (range O-366) min at the 
first PSG. The duration of nocturnal hypoxaemia had 
substantially decreased in nine subjects and had increased 
in six others by the time of the second PSG, but no 
significant change was noted for the group as a whole. 
Forty-three per cent (n=9) of our patients exhibited 
hypoxaemic periods lasting for at least 30 min during the 
two PSGs. Only two of these subjects developed daytime 
hypoxaemia after the second PSG. No daytime lung func- 
tion measurements or blood gas analyses could accurately 
predict the level or duration of nocturnal hypoxaemia. 
Reduced mean SaO, for the whole night at the second 
PSG correlated weakly with increased number of sleep 
stage changes per night (Fig. 1) and as well as prolonged 
sleep stage I (r= - 0.55, PcO.05) at the second PSG. Long 
duration of nocturnal hypoxaemic episodes at the second 
PSG also tended to correlate with an increase in sleep stage 
I (r=0.48, PcO.05). 
API,., APCO, - r and HCVR tended to be positively 
correlated among healthy controls (r=0.64, P=O.O5) but 
not among patients. 
Hypoxaemic periods were of equal frequency and equal 
duration during REM sleep and wakefulness. However, 




TABLE 3. Nocturnal hypoxaemic levels and nadir SaO, 
values during different sleep stages (7~~21) 
25 , 
PSG 1 PSG 2 
(Mean f SD) (Mean & SD) 
Baseline b (%) 
Mean SaO, (%) 
Mean hyp. SaO, (%) 
Nadir SaO, (%) 
St 0 (%) 
St I (%) 
St II (%) 
St III+Iv (%) 
REM (%) 
90.9 zk 2.1 
89.7 * 1.5 
88.0 dc 0.7 
82.6 k 4.6 
“86.4 k 1.5 
*86.7 * 1.2 
86.7 rt 1.6 
85.3 zt 3.2 
83.8 lk 4.9 
92.4 & 2.3 
90.6 f 2.4 
87.5 f 1.0 
82.2 f 4.4 
“86.3 zk 2.6 
“85.9 f 3.0 
85.6 f 2.9 
85.6 zt 2.7 
83.4 zt 5.0 
Baseline b, baseline supine SaO, at rest 15 min before sleep; 
mean SaO,, mean SaO, level during the whole night; mean 
hyp. SaO,, mean SaO, level during hypoxaemic periods 
during sleep. 
No significant changes occurred between PSG 1 and PSG 2. 





FIG. 2. Oxymetry tracing of hypoxaemic periods. Upper 
lane, ‘non-dipper’; lower lane, ‘dipper’. 
during wakefulness and sleep stage I at both the first and 
the second PSG (Table 3). No significant change occurred 
between PSG I and PSG II with regard to mean SaO, level 
at any sleep stage. 
Among the six patients who had SaO, dips at the first 
PSG (see Methods and Fig. 2), the median number of dips 
was four per night (range 3-9); while, among the 11 who 
‘dipped’ at the second PSG, the median number was three 
per night (range 1-12). By the time of the second PSG; the 
number of dips had increased in six patients and decreased 
in four (n.s.). The number of dips during REM sleep 
increased significantly (PcO.05) between the first and the 
second PSG (Fig. 3). Comparison at the second PSG 
between the seven patients who had at least three dips per 
night (‘dippers’) and the eight subjects who had no dips at 
all (‘non-dippers’) showed that the ‘dippers’ had lower FVC 
in %P, longer hypoxaemic episodes and lower nadir SaO,, 
longer absolute wakefulness, and tended to have a greater 
total number of sleep stage changes per night than the 
‘non-dippers’ (Table 4). It should be pointed out that 
0 I II III + IV REhiI 
Sleep stage 
FIG. 3. Total numbers of dips during different sleep 
stages. W, PSG 1; 0, PSG 2. *The total number of dips 
increased significantly during REM sleep (WO.05). 
patients classed as ‘dippers’ at the first PSG could be classed 
as ‘non-dippers’ at the second PSG and vice versa. Dips 
occurred with similar frequency in REM sleep and wake- 
fulness, but tended to occur less often in non REM sleep 
(Fig. 3). (Four patients who had l-2 dips per night were 
excluded from the comparisons shown in Table 4 because 
of the small number of subjects.) 
DAYTIME RESPIRATORY INSUFFICIENCY 
Seven patients (33%) died within a period of 3 years from 
the start of the study. All seven deceased subjects had a 
significantly lower mean body mass index (BMI) than the 
survivors (P<O.O5). Causes of death were confirmed by 
autopsy. Five subjects developed long-standing severe day- 
time hypoxaemia (PaO, ~7.5 kPa), and were given LTOT. 
Four out of these five patients died because of respiratory 
insufficiency within 1.5 years of first receiving oxygen 
therapy. Another two died in conjunction with acute 
exacerbations of their obstructive lung disease without 
prior development of long-term daytime hypoxaemia. 
Autopsy showed no signs of left heart failure in any of the 
seven deceased patients. Thus, the mortality rate was higher 
among subjects developing daytime hypoxaemia than 
among those with preserved daytime ‘normoxaemia’ 
(PCO.01). 
The five patients who subsequently developed long-term 
daytime hypoxaemia (=h patients) had significantly poorer 
lung function, lower HCVR, shorter proper sleep time; and 
were generally younger, than the 14 subjects with continued 
daytime ‘normoxaemia’ (=M patients) (Table 5). By the time 
of the second PSG, mean proper sleep time had been 
prolonged by 70%, and FVC%P had declined by 15% 
among the h patients. By contrast, mean proper sleep time 
had decreased by 2%, and FVC%P had increased by 14% 
among the IZ patients. The change in these two parameters 
differed significantly (PcO.05) between the two groups. 
There was no significant difference in hypercapnic 
respiratory drive response between the groups. The mean 
hypoxaemic level and nadir nocturnal SaO, value, as well 
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TABLE 4. Significant differences between non-dippers (eight patients) and dippers (seven patients) at 
the second polysomnography 
Non-dipper Dipper 
(Mean * SD) (Mean ?C SD) P-value 
FVC (%P) 
Hyp. time (min) 
Total wakefulness (min) 
Changes in sleep stages (n) 
Nadir SaO, (%) 
67.3 5 6.1 55.3 f 8.4 co.05 
13&20 179 * 118 0.01 
44&36 99&51 co.05 
524 13 65& 12 n.s. 
85.4 f 3.7 79.4 rt 4.2 co.05 
Hyp. time, total hypoxaemic time (SaO, ~90%) during nocturnal registration. 
TABLE 5. Significant differences between subjects with daytime normoxaemia [(n)= 141 and daytime 
hypoxaemia [(h) = 51 
PSG 1 
(Mean * SD) 
PSG 2 
(Mean f SD) 
Age (years) :;; 64 f 4 * 
56 f 8 * 
FVC (%P) g; 63.2 f 16.2 n.s. 68.4 f 15.8 * 
59.4 dz 13.8 n.s. 47.5 xt 12.7 
FEV, (%P) g; 27.5 k 7.3 
21.4 f 4.7 
::; 29.9 zt 8.3 r 
17.8 zt 2.6 1 
RV (%P) ii; 166.4 f 39.3 @I 159.0 Zt 43.1 * 
198.0 & 34.1 (b) 233.8 I!Z 48.4 * 
HCVR (1 min - ’ kPa - ‘) ;; 5.13 & 3.67 * 7.60 zk 4.29 * 
0.51 zk 0.93 1.01 f 1.76 * 
Pr. sl. time (min) g; 283 zt 70 ; 261 zt 63 ns. 
184~t67 t 287 zt 51 ns. 
Pr. sl. time, Sum of stages II, III, IV and REM sleep periods. 
For other abbreviations see previous tables and text. 
(a) P=O.O6, (b) P=O.O7, *P<O.O5, tP=O.Ol, $P<O.Ol. 
as the duration of nocturnal hypoxaemia and changes in 
these parameters over the year did not differ significantly 
between h and n patients. Median nadir SaO, decreased by 
two percentage points (n.s.) over the period for the h group, 
whereas it increased by one percentage point (n.s.) for the n 
group. 
Discussion 
The major findings of the study were as follows. No 
significant change in lung function or nocturnal hypoxae- 
mia was noted for the entire cohort during the year of 
observation. Hypercapnic respiratory drive response was 
within the normal range. A significant decrease in stage I 
sleep was noted. The appearance of daytime respiratory 
insufficiency in five of the patients was preceded by a 
substantial loss of airflow, but only by a minor long-term 
deterioration in nocturnal hypoxaemia. There was a high 
mortality rate, particularly among the patients receiving 
LTOT. 
MECHANISMS AND PATTERNS OF 
NOCTURNAL HYPOXAEMIA 
Similar to earlier studies (3,6,7,10), deeper nadir hypoxae- 
mia was noted during REM sleep than during wakefulness. 
However, in contrast to previous studies (3,6,7,10), no 
significant difference between duration of hypoxaemic 
periods during wakefulness or during REM sleep was 
detected in our patients. In concordance with earlier studies 
(2,3), sudden hypoxaemic dips were found to be more 
common in REM sleep than in non REM sleep. However, 
contrary to previous results (2,3), such dips were found to 
be as common during wakefulness as in REM sleep in our 
patients. 
This suggests that mechanisms other than the destabiliz- 
ing respiratory effects of REM sleep, such as increased 
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ventilation-perfusion inequality due to the supine position 
during sleep (23,24), might be of importance for inducing 
nocturnal hypoxaemic episodes in COPD patients. 
In Fletcher’s (25) prospective study, no significant change 
with regard to severity of nocturnal hypoxaemia was noted 
in COPD patients treated with either oxygen or compressed 
air at night. Our group of patients was similar to Fletcher’s 
study population with regard to severity of airway disease. 
However, our patients, who had not been given any gas 
treatment at all, showed no significant changes in duration 
or degree of nocturnal hypoxaemia. 
In most of our patients, mean SaO, during hypoxaemic 
episodes remained virtually unaltered; and in 40%, hypox- 
aemic episodes lasted longer than 30 min at both PSGs. 
Thus, substantial nocturnal hypoxaemia is, in many cases, 
not a transient condition, but exists for at least 1 year prior 
the development of daytime respiratory insufficiency. It was 
also noted that the duration of nocturnal hypoxaemia, 
nadir SaO, level, and a tendency to sudden SaO, dips, 
could vary considerably over time in the individual patient. 
QUALITY OF SLEEP 
It has previously been shown that increased frequency of 
wakenings correlates with reduced mean SaO, level during 
the whole night (16). In the present study, it was found that 
increased superficial (stage I) sleep and frequent sleep stage 
changes were associated with reduced level of whole night 
oxygenation. Increased stage I sleep was also noted in the 
patients with prolonged nocturnal hypoxaemic episodes. 
Those of our patients with many sudden dips in SaO, 
and relatively severe nocturnal hypoxaemia had longer 
periods of wakefulness and more frequent sleep stage 
changes than ‘non-dippers’ with less severe nocturnal 
hypoxaemia. Similar to previous studies (15,16), the rela- 
tionships between sleep quality parameters and degree of 
nocturnal hypoxaemia were found to be weak. However, 
five correlations and two group comparisons noted in the 
present study showed similar tendencies and taken together, 
indicated in all probability that severity of nocturnal 
hypoxaemia is associated with sleep disturbance. Disturbed 
sleep may thus be regarded as an important defence 
mechanism for maintaining high minute ventilation during 
sleep, preventing severe hypoxaemia (3,15,16). This 
assumption is supported by the observation at the begin- 
ning of our study that high daytime minute ventilation 
was associated with prolonged nocturnal wakefulness and 
frequent sleep stage changes. 
There was a small but significant reduction in superficial 
(stage I) sleep during the year of observation. Proper sleep 
time increased over the year for the subgroup with subse- 
quent development of daytime hypoxaemia so that these 
patients were similar to the rest of the patients regarding 
proper sleep time after 1 year of observation. Furthermore, 
in contrast with most previous studies of COPD patients 
and healthy controls (3,15,18), where deep non-REM sleep 
comprised only lo-15%, of the total sleep period. Our 
patients spent only about 20% of their total sleep period in 
stage II sleep, and as much as about 40% in deep non-REM 
sleep. It may be speculated that a reduction in superficial 
sleep and a high degree of deep non-REM sleep are signs 
heralding general exhaustion and deterioration in daytime 
and/or nocturnal oxygenation. This assumption is sup- 
ported by the finding in an earlier study (3) that nocturnal 
hypoxaemic episodes are frequent in COPD patients with a 
high amount of deep non-REM sleep and relatively few 
episodes of intervening wakefulness. The relationships 
between the progression of nocturnal hypoxaemia in COPD 
patients and changes in quality of sleep need to be further 
investigated. 
A contributing factor to the high amount of deep non- 
REM sleep found in our patients may be that the sleep 
recordings were performed after one night’s acclimatization 
to the measuring equipment. This procedure prolongs 
proper sleep time (13). Further, most of our patients had 
been treated in our hospital ward on several occasions 
before the PSGs were performed, and they were therefore 
well accustomed to the environment. Polysomnography at 
home in middle-aged healthy snorers has demonstrated a 
duration of deep non-REM sleep of about 25% of total 
sleep period (26). 
CARBON DIOXIDE RESPONSIVENESS 
The subjects in our study who subsequently developed 
daytime hypoxaemia had lower HCVR and also poorer 
lung function than the other patients. Further, HCVR was 
related to FEV, VC- ‘. These findings corroborate that 
ventilatory response in COPD patients, as well as in healthy 
individuals, is influenced by lung function (13,14). 
API,., dPC0, ~ i is dependent on the central respiratory 
drive as well as on respiratory muscle strength (13). Severe 
COPD patients without daytime respiratory insufficiency 
have been found to have a normal API,., LIPCO,-~ (27) 
which is achieved by using a higher proportion of 
maximal diaphragmatic muscle force than that of 
normal individuals. Further, inspiratory muscle strength is 
reduced in normoxic COPD patients with solely nocturnal 
hypoxaemia (8). 
The patients in our study who subsequently developed 
daytime hypoxaemia had more severe airway obstruction 
and hyperinflation, even before the appearance of daytime 
hypoxaemia, than those with preserved daytime ‘normox- 
aemia’. The subjects who eventually developed daytime 
hypoxaemia had, despite their severe lung-function impair- 
ment, a API,., dPC0, - i level similar to that found in our 
healthy controls. It may be speculated that this normal 
API,., &‘CO,- i level was achieved by utilizing a higher 
than normal proportion of maximal respiratory muscle 
force. This is supported by the finding at the start of our 
study that individuals with the most severe hyperinflation 
(which probably gives rise to reduced diaphragmatic muscle 
force) had the highest hypercapnic respiratory drive 
response. A high API,., &‘CO, - ’ value is likely to have 
contributed to our patients’ minute ventilation being higher 
than that of our healthy controls. 
API,., dPCO,-’ decreases with increasing age (28). In 
spite of this our patients had a hypercapnic respiratory 
drive response within the same range as noted in our 
younger controls. 
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THE IMPORTANCE OF LUNG FUNCTION 
Nocturnal hypoxaemia is associated with reduced daytime 
gas exchange and poor lung mechanics (1,2,23,24). Despite 
this, neither level nor duration of nocturnal hypoxaemia or 
hypoxaemic patterns were found to discriminate between 
patients who subsequently developed daytime hypoxaemia 
and those who did not. On the other hand, the patients in 
our present study who developed daytime hypoxaemia had 
significantly more pronounced airway obstruction than 
those with preserved ‘normoxaemia’ (Table 5). 
The appearance of daytime respiratory insufficiency was 
preceded by a substantial decrease in FVC (15%) in parallel 
with only a slight reduction in nadir SaO, (see Results). 
Conclusions 
The mean level of nocturnal hypoxaemia in COPD patients 
may persist unaltered for at least 1 year before the devel- 
opment of daytime respiratory insufficiency. However, 
nadir SaO, level, duration of nocturnal hypoxaemia, and 
tendency to oxygen-saturation dips may vary substantially 
over time in the individual subject. Nocturnal hypoxaemia 
is associated with a low daytime hypercapnic ventilatory 
response but with hypercapnic respiratory drive response 
within the normal range. Reduced average nocturnal oxy- 
genation is associated with increased superficial sleep and 
sleep stage changes. These findings suggest that mainten- 
ance of sleep fragmentation and high carbon dioxide 
sensitivity are important defence mechanisms against pro- 
gressive sleep-related hypoxaemia. The appearance of day- 
time hypoxaemia is preceded by a substantial deterioration 
in lung function, but by only a minor deterioration in 
nocturnal hypoxaemia. 
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